Literature DB >> 16869805

Racial and ethnic disparities in idiopathic pulmonary fibrosis: A UNOS/OPTN database analysis.

D J Lederer1, S M Arcasoy, R G Barr, J S Wilt, E Bagiella, F D'Ovidio, J R Sonett, S M Kawut.   

Abstract

We previously reported poorer survival among non-Hispanic blacks and Hispanics with idiopathic pulmonary fibrosis (IPF) compared to non-Hispanic whites at our center. In the current study, we hypothesized that these disparities would exist in a nationwide cohort of wait-listed patients with IPF. We performed a retrospective cohort study of 2635 patients with IPF listed for lung transplantation between 1995 and 2003 at 94 transplant centers in the United States. The age-adjusted mortality rate was higher among non-Hispanic blacks [hazard ratio (HR) = 1.24, 95% confidence interval (CI) 1.06-1.45, p = 0.009] and Hispanics (HR = 1.29, 95% CI 1.06-1.56, p = 0.01) compared to non-Hispanic whites. These findings persisted after adjustment for transplantation, medical comorbidities and socioeconomic status. Worse lung function at the time of listing appeared to explain some of these differences (HR for non-Hispanic blacks after adjustment for forced vital capacity percent predicted = 1.16, 95% CI 0.98-1.36, p = 0.09; HR for Hispanics = 1.21, 95% CI 0.99-1.48, p = 0.056). In summary, black and Hispanic patients with IPF have worse survival than whites after listing for lung transplant.

Entities:  

Mesh:

Year:  2006        PMID: 16869805      PMCID: PMC4153708          DOI: 10.1111/j.1600-6143.2006.01480.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  35 in total

1.  International guidelines for the selection of lung transplant candidates. The American Society for Transplant Physicians (ASTP)/American Thoracic Society(ATS)/European Respiratory Society(ERS)/International Society for Heart and Lung Transplantation(ISHLT).

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  1998-07       Impact factor: 21.405

2.  Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease.

Authors:  J D Hosenpud; L E Bennett; B M Keck; E B Edwards; R J Novick
Journal:  Lancet       Date:  1998-01-03       Impact factor: 79.321

3.  The epidemiology of interstitial lung diseases.

Authors:  D B Coultas; R E Zumwalt; W C Black; R E Sobonya
Journal:  Am J Respir Crit Care Med       Date:  1994-10       Impact factor: 21.405

4.  The effect of primary graft dysfunction on survival after lung transplantation.

Authors:  Jason D Christie; Robert M Kotloff; Vivek N Ahya; Gregory Tino; Alberto Pochettino; Christina Gaughan; Ejigayehu DeMissie; Stephen E Kimmel
Journal:  Am J Respir Crit Care Med       Date:  2005-03-11       Impact factor: 21.405

5.  Ethnic disparities in the treatment of stage I non-small cell lung cancer.

Authors:  Juan P Wisnivesky; Thomas McGinn; Claudia Henschke; Paul Hebert; Michael C Iannuzzi; Ethan A Halm
Journal:  Am J Respir Crit Care Med       Date:  2005-02-25       Impact factor: 21.405

6.  TNF-alpha, TGF-beta, IL-10, IL-6, and INF-gamma alleles among African Americans and Cuban Americans. Report of the ASHI Minority Workshops: Part IV.

Authors:  Nancy L Delaney; Violet Esquenazi; Donna P Lucas; Andrea A Zachary; Mary S Leffell
Journal:  Hum Immunol       Date:  2004-12       Impact factor: 2.850

7.  New predictors of outcome in idiopathic pulmonary arterial hypertension.

Authors:  Steven M Kawut; Evelyn M Horn; Ketevan K Berekashvili; Robert P Garofano; Rochelle L Goldsmith; Allison C Widlitz; Erika B Rosenzweig; Diane Kerstein; Robyn J Barst
Journal:  Am J Cardiol       Date:  2005-01-15       Impact factor: 2.778

8.  The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis.

Authors:  T S Hallstrand; L J Boitano; W C Johnson; C A Spada; J G Hayes; G Raghu
Journal:  Eur Respir J       Date:  2005-01       Impact factor: 16.671

9.  Idiopathic pulmonary fibrosis: survival in population based and hospital based cohorts.

Authors:  D W Mapel; W C Hunt; R Utton; K B Baumgartner; J M Samet; D B Coultas
Journal:  Thorax       Date:  1998-06       Impact factor: 9.139

10.  Pulmonary fibrosis deaths in the United States, 1979-1991. An analysis of multiple-cause mortality data.

Authors:  D M Mannino; R A Etzel; R G Parrish
Journal:  Am J Respir Crit Care Med       Date:  1996-05       Impact factor: 21.405

View more
  21 in total

Review 1.  Idiopathic pulmonary fibrosis-an epidemiological and pathological review.

Authors:  Andrea T Borchers; Christopher Chang; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

2.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

3.  Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension.

Authors:  Nicole B Gabler; Benjamin French; Brian L Strom; Ziyue Liu; Harold I Palevsky; Darren B Taichman; Steven M Kawut; Scott D Halpern
Journal:  Chest       Date:  2011-09-22       Impact factor: 9.410

4.  Racial and ethnic disparities in lung transplant listing and waitlist outcomes.

Authors:  Joshua J Mooney; Haley Hedlin; Paul Mohabir; Jay Bhattacharya; Gundeep S Dhillon
Journal:  J Heart Lung Transplant       Date:  2017-09-30       Impact factor: 10.247

5.  Idiopathic Pulmonary Fibrosis and the Elderly: Diagnosis and Management Considerations.

Authors:  Helen E Jo; Sharan Randhawa; Tamera J Corte; Yuben Moodley
Journal:  Drugs Aging       Date:  2016-05       Impact factor: 3.923

6.  The MUC5B promoter polymorphism is associated with idiopathic pulmonary fibrosis in a Mexican cohort but is rare among Asian ancestries.

Authors:  Anna L Peljto; Moises Selman; Dong Soon Kim; Elissa Murphy; Laura Tucker; Annie Pardo; Jung Su Lee; Wonjun Ji; Marvin I Schwarz; Ivana V Yang; David A Schwartz; Tasha E Fingerlin
Journal:  Chest       Date:  2015-02       Impact factor: 9.410

7.  Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study.

Authors:  Daniela J Lamas; Steven M Kawut; Emilia Bagiella; Nisha Philip; Selim M Arcasoy; David J Lederer
Journal:  Am J Respir Crit Care Med       Date:  2011-10-01       Impact factor: 21.405

8.  Race/ethnicity is associated with ABO-nonidentical liver transplantation in the United States.

Authors:  Jin Ge; John P Roberts; Jennifer C Lai
Journal:  Clin Transplant       Date:  2017-06-19       Impact factor: 2.863

9.  Disparities in lung transplantation before and after introduction of the lung allocation score.

Authors:  Keith M Wille; Kathy F Harrington; Joao A deAndrade; Sonia Vishin; Robert A Oster; Richard A Kaslow
Journal:  J Heart Lung Transplant       Date:  2013-04-09       Impact factor: 10.247

10.  Racial differences in waiting list outcomes in chronic obstructive pulmonary disease.

Authors:  David J Lederer; Emma K T Benn; R Graham Barr; Jessie S Wilt; Genevieve Reilly; Joshua R Sonett; Selim M Arcasoy; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2007-11-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.